Aveanna Healthcare (NASDAQ:AVAH) Raised to Strong-Buy at Raymond James Financial

Aveanna Healthcare (NASDAQ:AVAH) was upgraded by Raymond James Financial from an “outperform” rating to a “strong-buy” rating in a research report issued on Friday, MarketBeat reports. The brokerage currently has a $13.00 target price on the stock. Raymond James Financial’s price objective would suggest a potential upside of 97.72% from the company’s current price.

A number of other analysts also recently commented on AVAH. William Blair initiated coverage on Aveanna Healthcare in a research note on Monday, December 8th. They issued an “outperform” rating on the stock. Barclays boosted their price target on Aveanna Healthcare from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Friday, January 16th. Royal Bank Of Canada upped their price objective on Aveanna Healthcare from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research report on Thursday, January 15th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Monday, December 29th. Finally, Truist Financial set a $10.00 target price on shares of Aveanna Healthcare in a research note on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Aveanna Healthcare currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.06.

Aveanna Healthcare Stock Performance

NASDAQ:AVAH traded up $0.24 during mid-day trading on Friday, hitting $6.58. The company’s stock had a trading volume of 622,390 shares, compared to its average volume of 1,191,118. The business’s fifty day moving average is $7.88 and its two-hundred day moving average is $8.50. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of 18.26 and a beta of 2.07. The company has a debt-to-equity ratio of 140.39, a current ratio of 1.23 and a quick ratio of 1.23. Aveanna Healthcare has a 1 year low of $3.73 and a 1 year high of $10.32.

Insider Buying and Selling

In related news, CEO Jeff Shaner sold 173,225 shares of Aveanna Healthcare stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total value of $1,248,952.25. Following the sale, the chief executive officer owned 2,650,892 shares of the company’s stock, valued at approximately $19,112,931.32. This trade represents a 6.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Patrick A. Cunningham sold 18,436 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total transaction of $132,923.56. Following the completion of the sale, the insider directly owned 337,755 shares of the company’s stock, valued at approximately $2,435,213.55. The trade was a 5.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 998,595 shares of company stock valued at $7,567,770 in the last 90 days. Corporate insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On Aveanna Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd increased its stake in shares of Aveanna Healthcare by 252.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock worth $27,000 after purchasing an additional 2,400 shares in the last quarter. Quantbot Technologies LP purchased a new position in Aveanna Healthcare in the 2nd quarter valued at about $43,000. Oxford Asset Management LLP acquired a new stake in Aveanna Healthcare in the 2nd quarter worth about $64,000. Dynamic Technology Lab Private Ltd acquired a new stake in Aveanna Healthcare in the 2nd quarter worth about $68,000. Finally, PharVision Advisers LLC purchased a new stake in Aveanna Healthcare during the 2nd quarter worth approximately $78,000. 87.96% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Q4 results beat expectations — Aveanna reported a strong Q4 with EPS well above estimates and revenue that topped Street forecasts, driven by outsized year‑over‑year revenue growth. This demonstrates continued demand in its home‑health business. Read More.
• Positive Sentiment: Solid top‑line growth — revenue rose roughly in the high‑teens/20s percent year over year (company reported ~27.4% YoY increase), and several outlets note revenue and key metrics outperformed analyst estimates for the quarter. That supports the company’s growth narrative in medically complex home care. Read More.
• Neutral Sentiment: Earnings call/transcript available — management provided color on segment performance, margin drivers and operational cadence; read the transcript for details that could inform whether guidance is conservative or indicative of a trend. Read More.
• Neutral Sentiment: Short‑interest data reported in some feeds appears inconsistent/invalid (zero shares / NaN changes); current published short‑interest figures are not providing a clear signal on bearish positioning. (Data flagged by multiple services.)
• Negative Sentiment: Fiscal‑2026 guidance disappointed — management’s revenue outlook and growth guidance came in below consensus, and headlines focus on the guidance miss as the primary reason for the intraday sell‑off. That guidance shortfall is weighing on the stock despite the quarter’s beat. Read More.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.